Protocol Page


	Study ID (Protocol Number)
	AI447-029


	STUDY LOCATIONS*
	Alabama Liver & Digestive Specialists (Alds) Montgomery, AL 36116 Active, not recruiting	Baylor College Of Medicine Houston, TX 77030 Active, not recruiting
	Alamo Medical Research San Antonio, TX 78215 Active, not recruiting	Dean Clinic Madison, WI 53715 Active, not recruiting
	*Not all study site locations may be listed - please check back soon for updated information. For more information regarding other participating countries, please visit clinicaltrials.gov.

	STUDY NAME
	Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)
	STUDY OVERVIEW
	The purpose of this study is to assess efficacy, as determined by the proportion of subjects with Sustained Virologic Response at Post-Treatment Week 12 (SVR12), defined as Hepatitis C virus (HCV) Ribonucleic acid (RNA) < Limit of quantitation (LOQ) at post-treatment Week 12.

The study information provided here is a portion of what is available on ClinicalTrials.gov. Please visit ClinicalTrials.gov for complete information about this and other clinical studies.